- With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease FiercePharma
- Travere Therapeutics drug approved for rare kidney disease – STAT STAT
- Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
- US FDA approves Travere Therapeutics kidney disorder drug TODAY
- Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
- View Full Coverage on Google News
Read original article here